ASK REDCHAT ANYTHING ABOUT GYRE THERAPEUTICS INC.
Gyre Therapeutics Inc. (NASDAQ: GYRE)
Listen to this Section
$6.38
+0.1890
(
+3.05% )
82.4K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| AvatrombopagDetailsThrombocytopenia , Chronic liver disease |
Approved |
| F351 (Hydronidone)DetailsChronic hepatitis B, Liver fibrosis |
Phase 3 |
| F573DetailsAcute-on-Chronic liver failure |
Phase 2 |
| F351 (Hydronidone)DetailsNon-alcoholic steatohepatitis , Liver fibrosis |
Phase 2a |
Market Data
|
| Open |
$6.38 |
| Previous Close |
$6.19 |
| Volume |
82.4K |
| Market Cap |
$552.09M |
| Day Range |
$6.17 - $6.65 |
| 52 Week Range |
$5.44 - $9.42 |
| Shares Outstanding |
97.03M |
| Change % |
+3.05% |
| Net Change |
▲ 0.1890 |
| Insider Ownership |
-0.07% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2023 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-79,489,418.06
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-08-08 |
Sale |
-1866.00 |
Epstein David M. |
| 2024-07-01 |
Sale |
-3452.00 |
USMAN NASSIM |
| 2024-05-02 |
Sale |
-20000.00 |
USMAN NASSIM |
| 2024-04-03 |
Sale |
-20000.00 |
USMAN NASSIM |
| 2024-03-21 |
Sale |
-1866.00 |
Nussbaum Rodney L |
| 2024-03-19 |
Sale |
-20000.00 |
USMAN NASSIM |
| 2023-11-22 |
Sale |
-63588119.00 |
GNI Group Ltd. |
| 2023-11-22 |
Sale |
-1665115.00 |
Ye Weiguo |
| 2023-11-22 |
Sale |
-170417.00 |
Wu Charles C |
| 2023-11-22 |
Sale |
-4510047.00 |
Ma Songjiang |